Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti–PD1/PDL1 Clinical Trials

IMPORTANCE: Anti–programmed death 1 and anti–programmed death ligand 1 (anti–PD1/PDL1) immune checkpoint blockade (ICB) constitutes the therapeutic backbone for multiple malignant neoplasms. People living with HIV (PLWH) have routinely been excluded from ICB clinical trials, thus inhibiting broad im...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Netw Open
Hlavní autoři: Reuss, Joshua E., Stern, Diana, Foster, Jared C., Ramaswami, Ramya, Lurain, Kathryn, Chen, Helen X., Streicher, Howard, Kem, Ravie, Little, Richard F., Sharon, Elad
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2020
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709086/
https://ncbi.nlm.nih.gov/pubmed/33258905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.27110
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky